Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Pfizer
Jules Bordet Institute
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
Regeneron Pharmaceuticals
Alliance for Clinical Trials in Oncology
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Massachusetts General Hospital
H. Lee Moffitt Cancer Center and Research Institute
Iovance Biotherapeutics, Inc.
Massachusetts General Hospital
National Institutes of Health Clinical Center (CC)
Melanoma Institute Australia
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
British Columbia Cancer Agency
Memorial Sloan Kettering Cancer Center
Eastern Cooperative Oncology Group
Verrica Pharmaceuticals Inc.
Massachusetts General Hospital
Massachusetts General Hospital
The Center for Clinical and Cosmetic Research
University of Arizona
The Center for Clinical and Cosmetic Research
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
UNICANCER
Apexigen America, Inc.
Genmab
Dana-Farber Cancer Institute
Genmab
H. Lee Moffitt Cancer Center and Research Institute
Novartis
University of California, San Francisco
TriHealth Inc.
University of Rochester
Massachusetts Eye and Ear Infirmary
University of Wisconsin, Madison
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Celldex Therapeutics
National Cancer Institute (NCI)
Novartis
Stanford University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano